“÷Œò›ï46
|
|
|
- ひでたつ たもん
- 7 years ago
- Views:
Transcription
1 46
2 kgkg100 XCT100cm cm 2 85 cm90 cm OSCE OSCE
3 6 BMI 4.0g/ml RIA EIA ng/ml ng/ml c c d d d c c 7 9
4 mg/dl126mg/dl 3110mg/dl75g 140mg/dl LDL ,5-1,5-AG C- 75gOral Glucose Tolerance Test, OGTT75g GADglutamic acid decarboxylasegad 4 10 HDL LDL- HDL LDL-A-A- BC-C-ERLPremnant like particle LPa remnant-like lipoprotein choresterol 12 E C VLDL
5 2.20.1mg/dl mmhg WHOISH 140/90mmHg 3120/80mmHg 130/85mmHg130139/8589 mmhg 100mmHg mmHg 180mmHg MayoLudwing NASH 53050NASH nonalcholic fatty liver disease; NAFLDNASH NASHNAFLD1 15 CE NASH45 14 DRG/PPSDiagnosis-Related Group/Prospective Payment System
6 16 20g/ 15g/ ASTALT ASTBMI n kg/m BMI 25Kg/m 2 BMI Kg/m http://www2.ttcn.ne.jp/~honkawa/2240.html http://web-doctors.jp/sheets/002.html 5http://zyloric.jp/metabolic/cont02/index.html , DRG/PPS DRG/PPS RLP DRG/PPS van Dam RM et al: The relationship between overweight in adolescence and premature dealth in women 2006; Ann Interm Med
7 CBTComputer-based Testing OSCEObjective Structured Clinical Examination
8 SPstandardized patients OSCE OB OSCE 192OSCE OSCE OSCE HP(
9 32322 h OB ( ) (103) 91 () (114) ( )
10 M
11
12 Bayesian2American College of Clinical Pharmacology 2006 Annual MeetingPharmacokinetic and Pharmacodynamic Modeling course3win BUGS PKBugs4NONMEM TDM/ SPF 2SPF ID H 14 C 32 P MHz500MHz2FT- NMR(MS) GC-MSAUTO-MS ATR (IR) (LSM 12 NMRMSIR 20LSM NMRMSIR 18 3 MS MS )
13 54544 GIS GIS 500m GISWeb GIS GIS ( ) ( ) 110 ( ) ( ) 111 ( ) ( ) () (4-8-24) JR2 A2 0 () 1730 () 1,000 (1) 24 self-medpha.nihon-u.ac.jp
14
15 TEL
16 , % 97.50% % F () 2F 3F (45) MR computercbtcomputer based testingosceobjective structured clinical examination CBT CBT 43 OSCE m 2 611
17 Zygosaccharomyces rouxii Saccharomyces cerevisiae Z. rouxii S. cerevisiae S. cerevisiae 2 Z. rouxii S. cerevisiae Z. rouxii Z. rouxii S. cerevisiae S. cerevisiae Z. rouxii S. cerevisiae cdna9098
18 () (1) (90) (2) 19111()9() 11 14() 11 16() 1119()1130() Tel () 115 () AB ( ) ()28() 25() 27() 28()18(),,,, (1) (90) (2) 19111()() 1114() 1116() 1119()1130() Tel () 7/28 8/22
19 , , h A
20 OhMON CHOR (OB, OG) 10 Ave verum Corpus OG OBOG TEL & FAX ; kimura@pha.nihon-u.ac.jp
21 AED AED
22 () E-y-ogawa@pha.nihon-u.ac.jp E-kusamak@pha.nihon-u.ac.jp E-sudaatsu@pha.nihon-u.ac.jp FAX ,000 2
23 () 11: IT IT ( ) 1) ,5008,819 2) (1AED) () 1) 3 513() (USB) (12) OTC (26) (40) 2) 520() 561 (56,100) 484 ( 242,000) 3) ()9 (28) 4) ,000220,000310,000 (500) IT (IT) 1) HP () 1) 11 () 1) ,000 2) NL PRO() 210,000 3) ) 1 () 1) ) () 1)
24 () () 1) 19 10,000(8,000) 2) 300,000 (2,000 ) 1) ) , ) ( ) 4) () ()1 () 1) 18 18(19325) 2) () 1) 0.5 () 1) 19922() 1) 2) ) ) 19316() (M2 ) (4) (35) 14 19
25 MR, OTC CRO DMF OEM OTCOEM CPhI s_harada@ma.kitanet.ne.jp , 62, 85, , , ID ID ID 10 10IDID ID 10,, 71 a,,,,, h ,,,,,,, j,,,,, 16
26 , TEL FAX alumni@pha.nihon-u.ac.jp
“÷Œò›ï48
48 37 773 1 18 100 214 1 50 2 5 7 OSCE (Objective Structured Clinical Examination) 8 10 14 15 16 6 19 20 21 21 22 22 25 26 26 27 27 20 28 2 1 Over the counter 50 80 30 502 3 60 404 3 OTC OTCOver the counter
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
1. 2 2. 3 (1) 3 (2) 4 (3) 20 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 11 () 11 11 11 () 12 3 4 12 12 12 () 12 12 13 13 4. 14 (1) 14 () 14 () 14
![1. 2 2. 3 (1) 3 (2) 4 (3) 20 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 11 () 11 11 11 () 12 3 4 12 12 12 () 12 12 13 13 4. 14 (1) 14 () 14 () 14](/thumbs/41/22558859.jpg "1. 2 2. 3 (1) 3 (2) 4 (3) 20 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 11 () 11 11 11 () 12 3 4 12 12 12 () 12 12 13 13 4. 14 (1) 14 () 14 () 14")
ISSN1344 221X 1. 2 2. 3 (1) 3 (2) 4 (3) 20 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 11 () 11 11 11 () 12 3 4 12 12 12 () 12 12 13 13 4. 14 (1) 14 () 14 () 14 () 14 () 15 () 15 () 15 (2) 29 () 29
9 10 14 5 15 4 19 11 21 4 23 3 2012 24 11 24 5 24 6 27 2 447 52 395 27 2 1 2 3 4 5 6 7 8 9 10 11 12 (1) (2) (3) (4) 13 14 15 16 17 18 () 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
1 2014 10 1 1 2 1 3 2 3.1................ 2 3.2................ 2 4 3 5 5 5.1................. 5 5.2.................. 14 6 OB OG 22 7 22 8 22 1. 10 18 ( ) 91 48 2 12 20km 10 10 1 11 7 49 31 11 25 31 37
untitled
1 2 2 2 3 3 4 4 5 9 6 9 7 10 8 13 1 34 2 46 1 46 2 51 3 54 4 58 5 64 72 74 76 78 80 81 82 86 90 94 98 99 99 100 104 106 108 112 113 114 115 116 117 118 119 119 120 121 122 123 123 124 124 125 125 126 126
9 10 21 4 23 3 24 11 2012 24 5 28 4
9 10 21 4 23 3 24 11 2012 24 5 28 4 1 2 3 4 5 6 7 8 9 1 2 3 4 10 11 12 13 14 15 16 SIDS 17 18 19 20 21 22 1 2 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 1 2 3 4 5 6 01 3 4 P1 P P 10 11
函館市_絵で見てわかる
70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183
untitled
21 + TC : Toatal Choelesterol TGtriglyceride CE : cholesterol ester VLDLvery low density lipoprotein IDLintermediate density lipoprotein LDL low density lipoprotein HDL high density lipoprotein FFAfree
.y z...Z.I.v24...ren
63 2008 9 2009 3 2010 3 2.14 1.62 2011 3 2000 2005 64 1 1 1994 2004 3 40 60 2008 3 69.9 2009 94.9 1991 3 84 2009 2010 3 72.5 1991 84 2.86 2009 94.9 2.14 2010 72.5 1.62 1991 29.4 2000 41.2 2009 44.3 15
:30 100m 4 3 (2 ) 5 (3 ) 7 (1 ) 16 OB OG m 200m (2 ) m (1 ) 4 (3 ) 2m m 10:35 100m 3 (3 ) 5 OB OG (1
2003 10 1 1 1.1............ 1 1.2............ 2 1.3.......... 2 1.4.............. 2 1.5.............. 7 1.6.............. 10 2 11 100m,200m 200m 21 2.1............ 11 2m A 1 2.2.... 11 1500m 3 1 14m15
OBOG 3 OBOG OB OG 2 800m (3 ) (3 ) (4 ) 4 100mR 4 100mR OB OG :00 100m 3 (2 ) 5 (2 ) 6 (4 )
1 1 2 1 2.1................ 1 2.2.............. 2 2.3.................. 2 2.4.................. 11 3 14 3.1........... 14 3.2.............. 14 3.3.................. 23 4 23 4.1............... 23 4.2...............
“÷Œò›ï49
49 Epimedium chlorandrum Stearn 20 6 28 2 6 1. 2. 3. 4. 5. 6. 5653 11,0021,441 4 3 100 10 120 9 10 14 15 14 IT21 21 25 IT18 2020 33 6 6 2 3 6 Outstanding Student Award 6 7 14 17 18 21 19 19 20 20 21 22
untitled
1868 3 8 100 10 167-1 - 159 68 2012 10 KIITO KIITO 50 136 100-2 - - 3 - - 4-10 3 2012 5 8 11 25 2011 12 JR JR 15 TMOTown Management Organization TMO ( )NPO 80 2012 & 3 13301515 1 23 12 3.11-5 - 3GIS GIS
OBOG
2 40 OB 50 16 40 411 16 40 40 36 2 OB 50% 50% 3 40 10 20 80 OBOG 20 30 3 10 4 40 40 OB OB 8 41 42 5 43 6 27 3 3 No.1 25 100 100 40 100 7 8 OB 9 10 71 11 繫 72 81 12 82 13 14 OB OBOG 15 40 40 2 50 4 16 5
家庭系パソコンの回収再資源化にかかる論点
1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
OB OG (2 ) 2 (1 ) m 800m 3000m OB OG :30 100m 2 (2 ) 4 (4 ) 6 (3 )
2004 10 1 1 1.1............ 1 1.2............ 2 1.3.......... 2 1.4.............. 2 1.5.............. 7 1.6.............. 9 2 10 2.1............ 10 2.2....... 10 2.3...... 10 2.4............ 11 2.5..............
OB OB 3 2 OB 110 2
TEL:052-721-5351 FAX:052-723-6825 e-mail: yyyamajp@yahoo.co.jp chuma..ccnw.ne.jp - 21 OB 22 OB 21 22 22 21 Everything is made from a dream 37 19 19 12 21 12 OB 21 1 OB 61 100 110 8 110 OB 3 2 OB 110 2
E-mail CBT OSCE GP GP GP GP TEL OB OB MR MR My work & my favorite MR Apple ipad TV GFP GFP serendipity GFP GFP GFP GFP GFP TV CM JR NHK SL MOX NHK rd Keio University/Tamkang University
untitled
Ver.2018-1 http://www.kawasaki-net.ne.jp/robo 30 7 17 () ---------------------------------------------------------------------------------------------- 5 1 ---------------------------------------------------------------------------------------------------------
1990 1010 21 (1)(2) (3) (4) Vol. 21 No. 111999 3
201980Japan as number one 21American as number one 20 198020 19701980 1980 1990 2 Vol. 21 No. 111999 1990 1010 21 (1)(2) (3) (4) Vol. 21 No. 111999 3 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS
OB (2 ) 5 (4 ) m m 400m m 1 10: m 32 (2 ) ( m m m OB OG 800m 1200m 1.4 1
2004 9 OB 1 1 1.1............ 1 1.2............ 1 1.3.......... 2 1.4.............. 2 1.5.............. 5 2 2004 5 2004.9.18 7 3 OB 8 3.1 OB............. 8 3.2 OB............. 9 4 10 1 3 6 400m 49 7 4
<4D F736F F D208C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
28 6 IT 26 1 326 4,499 433 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
21 60 Vol. 21 No
3040 90 2 Vol. 21 No. 81999 21 60 Vol. 21 No. 81999 3 4444444444444444444444444444444444444444444444444444444 1830 10 12 1010 18 80 32 4 Vol. 21 No. 81999 Vol. 21 No. 81999 5 6 Vol. 21 No. 81999 Vol. 21
<4D F736F F D2095BD90AC E93785F8C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
29 7 IT 27 339 5,199 464 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
LDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
酵素化学
1 2 3 DNA RNA 4 5 6 7 8 9 H 2 O 10 http://www.ultranet.com/~jkimball/biologypages/c/carbohydrates.html#starches http://www.wantashi.com/aroma/refre/page12.html 11 mono : di : 2 tri : 3 poly : 12 13 14
レジャー産業と顧客満足の課題
1 1983 1983 2 3700 4800 5500 3300 15 3 100 1000 JR 4 14 2000 55% 72% 1878 2000 5 ( ) 22 1,040 5 946 42 15 25 30 30 4 14 39 1 24 8 6 390 33 800 34 34 3 35 () 37 40 1 50 40 46 47 2 55 4.43 4 16.98 40 55
2
1 2 2005 15 17 21 22 24 25 67 95 3 1 2 3 4 17 4 5 6 7 8 9 PR PR PR 10 11 12 PR 419 844 1,490 950 590 20 12 50 13 12/20 2/28 3/30 14 17 349 666 15 59 6 11 15 17 14 15 15 17 3,525,992 15 59 15 17 18 910
TRS4505.ec6..
糖尿病の療養指導 211 [ 日本糖尿病学会編 ] 別刷 レクチャー : 糖尿病療養指導に必要な知識 1 5 食後高血糖と脂質異常症の同時評価, 是正とその意義 原納 優, 前田亜耶, 名引順子, 原納晶著 211 年 9 月発行 発行所株式会社 診断と治療社 21 5 1 13 1,2 4 1 1 2 3 4 Key Words CMT Summary 154 CMT 1 IGT2 IFG3 1
21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13
訪問入浴Ｑ＆Ａ PDFファイ ル httpwww.care-mirai.commiraihomehelpe_buth.html.docx
4 450kg500kg 185cm 95kg 100kg 185 ( ) Vision , 40 8/138/15 1/11/3 1 13,000 11,700 9,500 3,500 13,000 11,700 9,500 3,500 http://www.care-mirai.com 1 37 38 1 1,000PPM soda premium 1,100ppm http://www.care-mirai.com/mirai/carbonated.html
橡ファミリー企業の分析020806
2002 8 6 1 700 OB 2000 700 ( 40 ) 82 5 613 2 700 5,000 2 1,000 700 3 87 4,542 2,533 (82 5 ) 700 OB 405 ( ) 2,500 ( ) (660 40 ) 4 82 5 700 82 5 613 5 30 30 30 30 6 (2001 ) ( ) 1,174 1,023 113 1,136 100
4 5 Y40 706050 70 14 29 C 8 A 2 M 5 E 11 W D 2 60 24 40 C 8 A 3 M 14 E 7 W 3 D 4 Y 50 34 99 C 16 A 15 M 17 E 17 W 12 D 12 Y 6 K 4 11 3 14 21 3 23 22 20 12 17 10 5 15 5 21 3 42 11 8 OB 62 42 104 261
Q A ワークショップ 肥 満 症 Q&A パート1 概 念 成 因 合 併 症 Q1: 長 谷 川 和 田 LDL HDL EPA LDL HDL EPA HDL CRP () 和 田 中 村 相 澤 Q2:HbA1C 長 谷 川 佐 藤 m
Vol. 17 No. 1 2011 トピック 日 本 肥 満 学 会 主 催 第 8 回 肥 満 症 サマーセミナー 特 集 日 本 肥 満 学 会 による 第 8 回 サマーセミナーが2010 年 8 月 28 日 ( 土 ), 新 潟 大 学 有 壬 記 念 館 にて 開 催 されました. ワークショップ 肥 満 症 Q&A から 興 味 深 い 討 論 をいくつか 取 り 上 げ, 本 号
MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2
2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.
A. B. C. D. E. GIO SBO, MR Medical representative CRO contract research organization,,, HIV MR MR MR MR MR CRO contract research organization CRA CRO CRA I IV, CBT OSCE CBT computer based testing OSCE
2
() () 980-8578 Tel: 022-795-6092 Fax: 022-795-6096 email: 1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 17 46 47 4.1.1
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
060407人材派遣業界における適正な健康保険年金制度の適用.doc
1 I.... 3 1.... 3 (1)... 3 (2)... 4 (3)...11 2....13 (1)...13 (2)...13 3....14...16 1....16 2....24...25 1....25 2....25 3....26 4....26 5....27 (1)...27 (2)...28 (3)...28 6....29 17 2 3 I. 1. (1) 1986
1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
: m 4 5 (3 ) A m : mH 110mH 1 6 (2 ) 5 8 (5 ) (1 ( )) / (
1 2014 5 1 1 1.1............... 1 1.2............... 1 1.3................ 2 1.4................ 13 2 2014.4.6 2014.5.25 16 3 2014 17 4 19 4.1 OB OG.......... 19 4.2................ 19 4.3 ( )............
(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (
![(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (](/thumbs/49/25497123.jpg "(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (")
ISSN1344221X 1. 2 2. 3 (1) 3 (2) 4 (3)19 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 12 () 13 () 13 3 4 13 14 14 () 14 14 14 14 4. 16 (1) 16 () 16 () 16 () 19 () 19 () 21 () 22 (2) 36 () 36 () 36 (3)
no
12 2004.9.3. no.234 2004.9.3. no.234 13 14 2004.9.3. no.234 2004.9.3. no.234 15 16 2004.9.3. no.234 2004.9.3. no.234 17 18 2004.9.3. no.234 19 2004.9.3. no.234 20 2004.9.3. no.234 21 2004.9.3. no.234 22
福島県2012-初校.indd
2012 FUKUSHIMA http://www.kairyudo.co.jp/ 2 4 5 1 2 3 2 3 20092008 kg cm 1500m 1000m 20m 50 m cm m 12 25.08 6.15 24.66 6.17 22.03 4.23 22.08 4.45 13 30.32 6.40 30.10 6.99 24.37 4.17 23.97 4.48 14 35.10
- 1 - - 0.5%5 10 10 5 10 1 5 1
- - - 1 - - 0.5%5 10 10 5 10 1 5 1 - 2 - - - - A B A A A B A B B A - 3 - - 100 100 100 - A) ( ) B) A) A B A B 110 A B 13 - 4 - A) 36 - - - 5 - - 1 - 6-1 - 7 - - 8 - Q.15 0% 10% 20% 30% 40% 50% 60% 70%
21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4
462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5
OB OG 3 1 2 (2 ) 800m (3 ) 5000mW 5m (4 ) 1 1.2 9:50 4 100mR 3 (4 )- -(M1)- (3 )- (3 ) 1 2 3 3 270m 4 2m 41 47 1 10:00 4 100mR 4 (2 ) (2 ) (4 ) (4 ) 4
1 1 1 1.1........... 1 1.2................ 2 1.3................ 14 2 2014.6.8 2014.7.5 18 3 2014 18 4 20 4.1 OB OG.......... 20 4.2................ 21 4.3 ( )............ 21 1 1.1 9 8 3 7 200M 3 21 95
untitled
. -28- 1 1 2-29- 11 USB -30- -31- -32- -33- -34- 11-35- 3-36- -37- 2-38- -39- -40- -41- -42- 11-43- -44- -45- 3-46- -47- 11-48- 1-49- -50- -51- -52- -53- -54- 1-55- 1 3-56- -57- -58- 11-59- -60- -61- 1-62-
EPSON
B K L & & & & & & & & L & & & & & & & K & & & & & L L L & & & K L L L & & L L L & & & & & & & & & & & & & & & & & & & & & & & & & & & L & K L K & & & & & & & L L & & L & & L L & & & & &
2.8% 2.0% 2.4% 2.4% 0.4% 0.1% 0.3% 0.5% 3.8% 5.6% 25.6% 29.3% 64.6% 60.0% 1
2.8% 2.0% 2.4% 2.4% 0.4% 0.1% 0.3% 0.5% 3.8% 5.6% 25.6% 29.3% 64.6% 60.0% 1 16 24 21 20 20 23 10 11 9 10 3 3 3 2 3 1 3 4 6 8 2 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 3 4 Q & A Q1 A1 Q2 A2 Q3 A3 7
Q&A最低資本金特例030131.PDF
& 1 2 2 3 2 2 3 2 2 3 10 11 10 90 12 13 14 15 16 17 18 19 20 2 2 3 21 2 2 3 22 23 24 25 20 10 26 27 28 10 8 1 29 30 10 8 2 31 32 2 2 3 33 10 8 3 10 11 2 34 10 8 3 10 12 2 35 36 20 10 37 38 39 40 41 42
™…
2/10 15 2010. No1362 1 1 216315 91430 Q A & 0.23% 1 1.4% 04-7120-2020 050-5540-2023 Q A & 1 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 1 2 3 4 5 6 7 8 9 10
‡o‡P†C‡P‡Q”R„û†^‡P†C‡P‡Q
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, Q & A ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2012_05_GLK_cover.indd
c %& r Z \ W W n q & F % % & & % & & % % % & % & % & % & % & % & F F % % % & & & & % & A
bumon_pro.indd
q w e r t y u i o!0 !1!2!3 !4!5!6 !7!8!9 @0 @1 @2 @3 @4 @5 @6 @7 @8 @9 #0 #1 #2 #3 #4 #5 #6 #7 #8 #0 $0 $1 $2 $3 $4 $5 $6 $7 $8 $9 %0 %1 %2 %3 %4 %5 %6 %7 %8 %9 ^0 ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 &0 &1 &2
2012_10_A_cover.indd
c %& r Z \ W n % & & % % & % & & % % % & % & % & & % & % %& % & % & % % % & & & W W W W A
BMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
HTML Search Engine Optimization SEO 3 [5] 2
![HTML Search Engine Optimization SEO 3 [5] 2](/thumbs/48/24245690.jpg "HTML Search Engine Optimization SEO 3 [5] 2")
(Shuji Mononobe) 2100 2013 4 29 2 1 Web 1. 2. 2 3. 4. [1] 2 [2] [3, 4] 1 HTML Search Engine Optimization SEO 3 [5] 2 4 2 3 5 Yahoo 5.1 SankeiBiz 2013/4/23 3 4 5.2 4 28 ( )... 5.3 4 28 ( ) 5 :4 28 ( )12
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
ありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%